Multiple genetic variants predict the progression-free survival of bevacizumab plus chemotherapy in advanced ovarian cancer: A retrospective study

Bevacizumab (BV) plus chemotherapy is broadly used in advanced ovarian cancer (OC). However, the efficacy of BV-based regimens for advanced OC patients is not satisfactory. Therefore, it is urgent to explore the predictive genetic biomarkers for BV. Tumor tissues from advanced OC patients receiving...

Descripción completa

Detalles Bibliográficos
Autores principales: Gao, Jie, Li, Fang, Liu, Zihao, Huang, Mengli, Chen, Huoming, Liao, Guoqing, Meng, Jichang, Wang, Qing, Zhao, Hui, Li, Chenxi, Ji, Jing, Cai, Shangli, Du, Nan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2021
Materias:
5700
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8415939/
https://www.ncbi.nlm.nih.gov/pubmed/34477158
http://dx.doi.org/10.1097/MD.0000000000027130

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8415939/
https://www.ncbi.nlm.nih.gov/pubmed/34477158
http://dx.doi.org/10.1097/MD.0000000000027130

Ejemplares similares